AUTHORS
Sutapa Sinha, PhD, Panwen Wang, MS, PhD2, Hugues Sicotte, Ph.D3, Brianna M Finke4, Jacob A Ray5, Heather C Darby6, Miles D Del Busso7, Zhiquan Wang, Ph.D8, Min Shi, M.D.9, Esteban Braggio, PhD10, Paul J. Hampel, MD11, Sameer A. Parikh, MBBS12, Saad Kenderian, M.B., Ch.B.13, Neil E Kay, M.D.14
AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Scottsdale, AZ, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Scottsdale, Arizona, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Introduction: Richter transformation (RT), in Chronic Lymphocytic Leukemia (CLL), remains associated with poor clinical outcomes and limited treatment responses. A better understanding of the genetic and immune changes underlying the transition from CLL to RT may provide insights into disease pathogenesis and support the development of more effective therapies.
Methods: We utilized a unique cohort of RT patients (n=11) with prospectively collected paired and sequential blood samples both from the time of diagnosis of CLL and RT. We performed single cell (sc) RNA-sequencing (seq), sc T cell receptor (TCR)-seq, sc B cell receptor (BCR)-seq with sorted T and B cells from peripheral blood mononuclear cells and whole exome sequencing (WES) with sorted leukemic B cells. Comparison of scRNA-seq data from paired CLL and RT samples was performed using the immunopipe (v2.5.3) which incorporates Seurat (v5.4.0). Integrated analysis of scRNA-seq -gene expression (GEX) data and sc-TCR (GEX+TCR) or BCR (GEX+BCR) repertoire-seq data was done using scRepertoire v2.2.1 and visualized with scplotter (v0.7.4). The WES analysis of tumor B cells of paired CLL & RT samples was done using the Agilent Sureselect Human all exon v5+UTR capture kit. Reads from paired end sequencing were processed with the sarek pipeline. Somatic mutation clustering was done using PyClone and compared the clonality of each cluster in CLL and RT samples using t-tests (2 samples) or ANOVA (>2 samples).
Results: scRNA-seq GEX data from paired samples showed a trend towards an increase of CD8 effector memory and a decreasing trend of CD4 central memory (TCM) and CD4 naïve T cells among the 13 T cell clusters in RT versus (vs.) CLL stage. However, no changes were detected among the 3 identified B cell subsets (Naïve, intermediate, memory). Identification of the top 5 differentially expressed genes/cluster indicated significant changes in long non-coding (lnc)RNA FP236383.3 of current unknown function in all 13 T and 3 B cell subsets of RT vs. CLL samples. Additionally, we observed differential changes in the levels of NKG7, GNLY, STMN1, GZMK, PCLAF, CCL5, HLA-DQA1 in CD8 Naïve T cells; TCL1A, IL7R, IL32, CCL5, GNLY, NKG7, TCF7 in intermediate B and TCL1A, CCL5, TCF7, GNLY, NKG7, CD7 in memory B cells of RT vs. CLL samples (Log2FC≥1, padj<0.05). Comparing cytotoxic T, helper T, activation and exhaustion marker genes across T cell populations, we found that the most profound differential gene expression changes were observed in CD4 TCM, CD8 Naïve- and gd-T cells (Log2FC≥1, padj<0.05) of RT vs. CLL samples. The top 10 altered pathways in CD8 Naïve T, CD4 TCM, intermediate B, naïve B and memory B cells of RT compared to CLL included IFN-γ response, TNF-α signaling, allograft rejection, Myc targets V1, oxidative phosphorylation, complement, inflammatory response, mTORC1, E2F targets and G2M checkpoint signaling. Analysis of GEX+TCR data revealed that patients at the RT stage showed a trend towards lower clonal richness and lower evenness indicating a higher number of hyperexpanded clones compared to their paired CLL samples. GEX+BCR data also indicated a trend towards decreased clonal richness - but increased evenness of the B cell clones in RT vs. CLL. Moreover, the distribution of the top 10 GEX+TCR/GEX+BCR clones differed significantly between paired CLL and RT samples. WES data revealed that the most frequently mutated gene is TP53 in leukemic B cells of both CLL and RT stage samples. However, a higher percentage of RT samples carry mutations in MGA, ATM, and IRF2BP2 genes vs. their CLL stage. PyClone analysis of clonal evolution using WES data from the paired samples revealed shifts in relative frequencies of existing clonal populations between CLL and RT samples.
Conclusion: Transformation of CLL to RT associated with significant transcriptional, signaling pathways and clonal remodeling in B and T cell subsets at the RT stage despite limited changes in subset frequencies. Changes in TCR and BCR repertoire abundance, diversity and relative abundance of tumor subclones indicated significant immune dysregulation and clonal evolution in RT stage. Genomic data also indicated an altered mutational signature between CLL and RT paired samples. Ongoing accrual and analysis of paired CLL and RT patient samples will further strengthen our current findings, improve risk stratification and our pathobiological knowledge of CLL patients transitioning to RT.
DISCLOSURES
Sutapa Sinha, PhD: No relevant conflicts of interest to declare.